title: Palivizumab for prophylaxis of RSV infection: five epidemic seasons' experience on adverse effects (2002-2007).
authors.forename: Stefano
authors.initials: S
authors.lastname: Parmigiani
authors.forename: Silvia
authors.initials: S
authors.lastname: Pezzoni
authors.forename: Elena
authors.initials: E
authors.lastname: Solari
authors.forename: Vittoria
authors.initials: V
authors.lastname: Arena
authors.forename: Arianna
authors.initials: A
authors.lastname: De Martino
authors.forename: Cristina
authors.initials: C
authors.lastname: Alessandrini
authors.forename: Sabrina
authors.initials: S
authors.lastname: Moretti
authors.forename: Giulio
authors.initials: G
authors.lastname: Bevilacqua
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000009:adverse effects*; D001997:Bronchopulmonary Dysplasia; D018890:Chemoprevention / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab